

REMARKS/ARGUMENTS


Claims 1-7 and 9 have been amended. Claims 8 and 10 have been cancelled. Claims 11 – 17 have been added. The amendments have been made to remove multiple dependencies, to cancel claims that do not conform to US practice (claim 8 to “compound for use” and omnibus claim 10), and to add claims to individual disclosed compounds. No new matter has been added.

Fees pursuant to 37 C.F.R. 1.492 have been paid in accordance with the transmittal letter submitted herewith and are believed to be sufficient. If an additional fee is required, however, please charge the same (or credit any surplus) to Deposit Account 50-3464.

Applicant earnestly solicits early examination and allowance of these claims. In the event there are any questions, please do not hesitate to contact the undersigned by telephone.

Respectfully submitted,

Dated: April 7, 2006

By 

Thomas Hoxie
Reg. No. 32,993

HOXIE & TSO LLP
374 Millburn Avenue, Ste 300E
Millburn, NJ 07041
(973) 467-2126